Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Cash from Financing Activities (2020 - 2025)

Historic Cash from Financing Activities for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to $50.0 million.

  • Lyell Immunopharma's Cash from Financing Activities changed N/A to $50.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.6 million, marking a year-over-year increase of 297166.26%. This contributed to the annual value of $1.3 million for FY2024, which is 2392.43% down from last year.
  • Latest data reveals that Lyell Immunopharma reported Cash from Financing Activities of $50.0 million as of Q3 2025.
  • Lyell Immunopharma's 5-year Cash from Financing Activities high stood at $393.5 million for Q2 2021, and its period low was -$531000.0 during Q3 2021.
  • In the last 5 years, Lyell Immunopharma's Cash from Financing Activities had a median value of $862500.0 in 2022 and averaged $25.8 million.
  • Over the last 5 years, Lyell Immunopharma's Cash from Financing Activities had its largest YoY gain of 208905.33% in 2021, and its largest YoY loss of 161714.29% in 2021.
  • Over the past 5 years, Lyell Immunopharma's Cash from Financing Activities (Quarter) stood at $7.4 million in 2021, then crashed by 88.34% to $863000.0 in 2022, then dropped by 12.05% to $759000.0 in 2023, then tumbled by 42.42% to $437000.0 in 2024, then soared by 11341.65% to $50.0 million in 2025.
  • Its last three reported values are $50.0 million in Q3 2025, $183000.0 for Q2 2025, and $1000.0 during Q1 2025.